Theravance Biopharma (NASDAQ:TBPH) Upgraded to "Strong-Buy" at B. Riley

Key Points

• Theravance Biopharma has received a "strong-buy" rating upgrade from B. Riley, reflecting growing confidence in the company's prospects.
• Other research analysts have also indicated positive sentiments, with BTIG Research raising its price target from $24.00 to $25.00 and multiple upgrades from "hold" to "strong-buy" by firms including Zacks Research and Jones Trading.
• The stock has seen a 4.4% increase recently, with a current market price of $14.30 and an average target price of $23.00 according to MarketBeat.com.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) was upgraded by B. Riley to a "strong-buy" rating in a report released on Thursday, September 11th,Zacks.com reports.

A number of other analysts have also recently weighed in on the stock. BTIG Research boosted their price objective on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Friday, June 27th. Wall Street Zen upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research note on Tuesday, June 17th. Finally, Zacks Research upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 15th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Theravance Biopharma has a consensus rating of "Buy" and an average target price of $23.00.

Theravance Biopharma Trading Up 1.2%

NASDAQ TBPH traded up $0.17 during trading on Thursday, reaching $14.22. The company's stock had a trading volume of 118,488 shares, compared to its average volume of 294,231. The stock has a market capitalization of $716.12 million, a PE ratio of 59.25 and a beta of 0.05. The business has a 50-day moving average price of $12.56 and a 200-day moving average price of $10.69. Theravance Biopharma has a 1-year low of $7.88 and a 1-year high of $14.55.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the transaction, the senior vice president owned 326,918 shares of the company's stock, valued at approximately $3,723,596.02. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC increased its holdings in Theravance Biopharma by 1,201.8% in the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 3,281 shares during the period. Tower Research Capital LLC TRC lifted its position in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after purchasing an additional 781 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Theravance Biopharma in the 1st quarter valued at approximately $101,000. R Squared Ltd raised its position in shares of Theravance Biopharma by 636.6% in the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock valued at $112,000 after acquiring an additional 10,822 shares during the period. Finally, Creative Planning bought a new stake in Theravance Biopharma during the 2nd quarter worth approximately $139,000. Institutional investors own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.